ATE447974T1 - Kombinationstherapie mit azd2171 und 5-fu und/oder cpt-11 - Google Patents

Kombinationstherapie mit azd2171 und 5-fu und/oder cpt-11

Info

Publication number: ATE447974T1
Authority: AT; Austria
Prior art keywords: cpt; azd2171; human; combination therapy; antiangiogenic
Prior art date: 2004-03-23

Application number

AT05729381T

Other languages

English (en)

Inventor

Stephen Robert Wedge

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-23

Filing date

2005-03-22

Publication date

2009-11-15

2005-03-22 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2009-11-15 Application granted granted Critical

2009-11-15 Publication of ATE447974T1 publication Critical patent/ATE447974T1/de

Links

GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title abstract 11
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title abstract 11
XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 title abstract 6
229960002412 cediranib Drugs 0.000 title abstract 6
238000002648 combination therapy Methods 0.000 title 1
241001465754 Metazoa Species 0.000 abstract 3
206010028980 Neoplasm Diseases 0.000 abstract 3
238000004519 manufacturing process Methods 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
230000001772 anti-angiogenic effect Effects 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 2
230000005855 radiation Effects 0.000 abstract 2
230000001603 reducing effect Effects 0.000 abstract 2
230000008728 vascular permeability Effects 0.000 abstract 2
239000013066 combination product Substances 0.000 abstract 1
229940127555 combination product Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Immunology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Iron Core Of Rotating Electric Machines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

AT05729381T 2004-03-23 2005-03-22 Kombinationstherapie mit azd2171 und 5-fu und/oder cpt-11 ATE447974T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0406446.5A GB0406446D0 (en)	2004-03-23	2004-03-23	Combination therapy
PCT/GB2005/001080 WO2005092303A2 (en)	2004-03-23	2005-03-22	Combination therapy with azd2171 and 5-fu and/or cpt-11

Publications (1)

Publication Number	Publication Date
ATE447974T1 true ATE447974T1 (de)	2009-11-15

Family

ID=32188482

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05729381T ATE447974T1 (de)	2004-03-23	2005-03-22	Kombinationstherapie mit azd2171 und 5-fu und/oder cpt-11

Country Status (18)

Country	Link
US (1)	US20080125447A1 (de)
EP (1)	EP1729808B1 (de)
JP (1)	JP2007530518A (de)
KR (1)	KR20060130763A (de)
CN (1)	CN1964742A (de)
AT (1)	ATE447974T1 (de)
AU (1)	AU2005225193B2 (de)
BR (1)	BRPI0508982A (de)
CA (1)	CA2610628A1 (de)
DE (1)	DE602005017591D1 (de)
ES (1)	ES2335292T3 (de)
GB (1)	GB0406446D0 (de)
IL (1)	IL177952A0 (de)
MX (1)	MXPA06010758A (de)
NO (1)	NO20064755L (de)
NZ (1)	NZ549553A (de)
WO (1)	WO2005092303A2 (de)
ZA (1)	ZA200607555B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0008269D0 (en)	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
GB0330002D0 (en) *	2003-12-24	2004-01-28	Astrazeneca Ab	Quinazoline derivatives
BRPI0508959A (pt) *	2004-03-23	2007-08-14	Astrazeneca Ab	uso de azd2171 ou de um sal do mesmo farmaceuticamente aceitável, uso de sal maleato de azd2171 e oxaliplatina, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
EP1901754A2 (de) *	2005-07-06	2008-03-26	AstraZeneca AB	Kombinationstherapie gegen krebs mit azd2171 und gemcitabin
KR20080077678A (ko) *	2005-12-22	2008-08-25	아스트라제네카 아베	Ａｚｄ2171 및 페메트렉시드의 조합물
WO2015082880A1 (en) *	2013-12-02	2015-06-11	Astrazeneca Ab	Methods of selecting treatment regimens
WO2020061391A1 (en) *	2018-09-20	2020-03-26	The Trustees Of Columbia University In The City Of New York	Methods for inhibiting tumor cells using inhibitors of foxo3a antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6811779B2 (en) *	1994-02-10	2004-11-02	Imclone Systems Incorporated	Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
EE05345B1 (et) *	1999-02-10	2010-10-15	Astrazeneca Ab	Kinasoliini derivaadid angiogeneesi inhibiitoritena
US7740841B1 (en) *	2000-01-28	2010-06-22	Sunnybrook Health Science Center	Therapeutic method for reducing angiogenesis
TWI310684B (en) *	2000-03-27	2009-06-11	Bristol Myers Squibb Co	Synergistic pharmaceutical kits for treating cancer
CN1551767A (zh) *	2001-02-19	2004-12-01	��˹��ŵ��	癌症的治疗
US20050043233A1 (en) *	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0310401D0 (en) *	2003-05-07	2003-06-11	Astrazeneca Ab	Therapeutic agent
EP1796672A1 (de) *	2004-09-27	2007-06-20	AstraZeneca AB	Kombinationstherapie gegen krebs mit azd2171 und imatinib
EP1901754A2 (de) *	2005-07-06	2008-03-26	AstraZeneca AB	Kombinationstherapie gegen krebs mit azd2171 und gemcitabin
EP1962903B1 (de) *	2005-12-15	2013-03-13	MedImmune Limited	Kombination eines angiopoetin-2-antagonisten und eines vegf-a, kdr- und/oder fltl-antagonisten zur behandlung von krebs
KR20080077678A (ko) *	2005-12-22	2008-08-25	아스트라제네카 아베	Ａｚｄ2171 및 페메트렉시드의 조합물

2004
- 2004-03-23 GB GBGB0406446.5A patent/GB0406446D0/en not_active Ceased
2005
- 2005-03-22 MX MXPA06010758A patent/MXPA06010758A/es active IP Right Grant
- 2005-03-22 CA CA002610628A patent/CA2610628A1/en not_active Abandoned
- 2005-03-22 AU AU2005225193A patent/AU2005225193B2/en not_active Ceased
- 2005-03-22 US US10/594,233 patent/US20080125447A1/en not_active Abandoned
- 2005-03-22 BR BRPI0508982-4A patent/BRPI0508982A/pt not_active IP Right Cessation
- 2005-03-22 DE DE602005017591T patent/DE602005017591D1/de not_active Expired - Lifetime
- 2005-03-22 CN CNA2005800092182A patent/CN1964742A/zh active Pending
- 2005-03-22 WO PCT/GB2005/001080 patent/WO2005092303A2/en not_active Ceased
- 2005-03-22 JP JP2007504467A patent/JP2007530518A/ja active Pending
- 2005-03-22 EP EP05729381A patent/EP1729808B1/de not_active Expired - Lifetime
- 2005-03-22 AT AT05729381T patent/ATE447974T1/de not_active IP Right Cessation
- 2005-03-22 NZ NZ549553A patent/NZ549553A/en unknown
- 2005-03-22 ES ES05729381T patent/ES2335292T3/es not_active Expired - Lifetime
- 2005-03-22 KR KR1020067021774A patent/KR20060130763A/ko not_active Ceased
2006
- 2006-09-07 IL IL177952A patent/IL177952A0/en unknown
- 2006-09-08 ZA ZA200607555A patent/ZA200607555B/en unknown
- 2006-10-20 NO NO20064755A patent/NO20064755L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE602005017591D1 (de)	2009-12-24
BRPI0508982A (pt)	2007-08-28
IL177952A0 (en)	2007-07-04
WO2005092303A3 (en)	2006-11-02
HK1096023A1 (en)	2007-05-25
AU2005225193A1 (en)	2005-10-06
CN1964742A (zh)	2007-05-16
GB0406446D0 (en)	2004-04-28
AU2005225193B2 (en)	2008-10-09
ZA200607555B (en)	2008-05-28
WO2005092303A2 (en)	2005-10-06
KR20060130763A (ko)	2006-12-19
EP1729808B1 (de)	2009-11-11
CA2610628A1 (en)	2005-10-06
US20080125447A1 (en)	2008-05-29
NO20064755L (no)	2006-10-20
MXPA06010758A (es)	2006-12-15
EP1729808A2 (de)	2006-12-13
NZ549553A (en)	2009-12-24
JP2007530518A (ja)	2007-11-01
ES2335292T3 (es)	2010-03-24

Legal Events

Date	Code	Title	Description
2010-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
SI1551409T1 (sl)	2007-08-31	Uporaba kinazolinskega derivata ZD6474, kombiniranega z gemcitabinom in po želji ionizirajočim obsevanjem, pri zdravljenju raka
CY1111547T1 (el)	2015-08-05	Συνδυασμος zd6474 και πεμετρεξεδης
CY1111482T1 (el)	2015-08-05	Συνδυασμος azd2171 και πεμετρεξεδης
MX2007003505A (es)	2007-05-10	Combinacion que comprende zd6474 e imatinib.
MXPA05008583A (es)	2005-11-04	Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
DE602005017591D1 (de)	2009-12-24	Kombinationstherapie mit azd2171 und 5-fu und/oder cpt-11
PL1653964T3 (pl)	2009-01-30	Skojarzone leczenie raka obejmujące AZD2171 i ZD1839
NO20064754L (no)	2006-10-20	Kombinasjonsterapi
NO20076657L (no)	2008-04-03	Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
NO20056171L (no)	2006-02-07	Kombinasjonsterapi
WO2005092384A3 (en)	2006-11-02	Combination therapy with azd2171 and a platinum anti-tumour agent